Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...